PD GSK3 Inhibitor Companies
Overview
flowchart TD
companies_pd_gsk3_inhibitor_co["PD GSK3 Inhibitor Companies"]
companies_pd_gsk3_inhibitor_co["Glycogen"]
companies_pd_gsk3_inhibitor_co -->|"related to"| companies_pd_gsk3_inhibitor_co
style companies_pd_gsk3_inhibitor_co fill:#81c784,stroke:#333,color:#000
companies_pd_gsk3_inhibitor_co["synthase"]
companies_pd_gsk3_inhibitor_co -->|"related to"| companies_pd_gsk3_inhibitor_co
style companies_pd_gsk3_inhibitor_co fill:#81c784,stroke:#333,color:#000
companies_pd_gsk3_inhibitor_co["kinase"]
companies_pd_gsk3_inhibitor_co -->|"related to"| companies_pd_gsk3_inhibitor_co
style companies_pd_gsk3_inhibitor_co fill:#81c784,stroke:#333,color:#000
companies_pd_gsk3_inhibitor_co["beta"]
companies_pd_gsk3_inhibitor_co -->|"related to"| companies_pd_gsk3_inhibitor_co
style companies_pd_gsk3_inhibitor_co fill:#81c784,stroke:#333,color:#000
style companies_pd_gsk3_inhibitor_co fill:#4fc3f7,stroke:#333,color:#000
Glycogen synthase kinase 3 beta (GSK-3beta) is a serine/threonine kinase that plays a central role in Parkinson's disease pathogenesis through its effects on tau hyperphosphorylation, alpha-synuclein (alpha-syn) phosphorylation and aggregation, mitochondrial dysfunction, and neuroinflammation. GSK-3beta represents one of the most compelling therapeutic targets for disease modification in PD["@gsk3_parkinsons_review"].
GSK3β in Parkinson's Disease Pathogenesis
...PD GSK3 Inhibitor Companies
Overview
Mermaid diagram (expand to render)
Glycogen synthase kinase 3 beta (GSK-3beta) is a serine/threonine kinase that plays a central role in Parkinson's disease pathogenesis through its effects on tau hyperphosphorylation, alpha-synuclein (alpha-syn) phosphorylation and aggregation, mitochondrial dysfunction, and neuroinflammation. GSK-3beta represents one of the most compelling therapeutic targets for disease modification in PD["@gsk3_parkinsons_review"].
GSK3β in Parkinson's Disease Pathogenesis
GSK-3β is constitutively active in neurons and its activity is regulated by inhibitory phosphorylation at Ser9. In PD, this inhibitory mechanism is impaired, leading to increased kinase activity that promotes pathological protein aggregation and neuronal death. The kinase also phosphorylates α-syn at Ser129, a modification abundant in Lewy bodies[@gsk3_alpha_syn].
Tau Hyperphosphorylation
GSK-3β is one of the principal kinases responsible for tau hyperphosphorylation in PD, phosphorylating tau at multiple sites including Thr181, Ser202, Thr205, Ser396, and Ser404, promoting microtubule disassembly and neurofibrillary tangle formation.
Alpha-Synuclein Phosphorylation
GSK-3β phosphorylates α-syn at multiple sites, with Ser129 being the most studied. The relationship between GSK-3β activity and α-syn pathology is context-dependent.
Mitochondrial Dysfunction
GSK-3β contributes to mitochondrial dysfunction in PD through inhibition of mitochondrial biogenesis via PGC-1α, promotion of mitochondrial permeability transition, regulation of mitophagy through Parkin and PINK1, and enhancement of mitochondrial oxidative stress.
Companies Developing GSK3 Inhibitors for PD
Lithium-Based Approaches
Lithium is a first-generation GSK3 inhibitor used clinically for bipolar disorder. It inhibits GSK-3β both directly and indirectly through Akt-mediated Ser9 phosphorylation[@lithium_parkinsons]:
- Lithium carbonate formulations: Generic, widely available, brain-penetrant
- Lithium orotate: Alternative formulation with different pharmacokinetics
Selective GSK3 Inhibitors
Tideglusib (Neuroab)
Tideglusib is a selective, irreversible GSK3 inhibitor developed by Nostrum. It has been evaluated in clinical trials for Alzheimer's disease with a favorable safety profile[@tideglusib_trials]:
- Target: GSK-3α and GSK-3β
- Status: Completed Phase II for AD
- PD potential: Targets tau and α-syn phosphorylation
AR-A014418
AR-A014418 is a selective ATP-competitive GSK3 inhibitor developed by AstraZeneca:
- Target: GSK-3β (selective)
- Evidence: Neuroprotective in MPTP models
CHIR99021
CHIR99021 is a selective GSK3 inhibitor used in research to enhance Wnt signaling:
- Target: GSK-3β (selective)
- Evidence: Promotes dopaminergic neuron survival
Clinical Trial Landscape
Completed Trials
| Compound | Indication | Phase | Status |
|----------|------------|-------|--------|
| Tideglusib | Alzheimer's | Phase II | Completed |
| Lithium | PD | Various | Completed |
Therapeutic Development Challenges
- Selectivity: Difficulty achieving isoform selectivity between GSK-3α and GSK-3β
- Brain Penetration: Many early inhibitors failed to achieve adequate brain penetration
- Therapeutic Window: Narrow window between neuroprotective and toxic doses
- Mechanism Complexity: Dual role of GSK-3β in both promoting and potentially preventing α-syn aggregation
Conclusion
GSK3β represents a compelling therapeutic target in Parkinson's disease. While no selective GSK3 inhibitors have reached late-stage clinical development specifically for PD, lithium remains the most clinically tested GSK3 inhibitor for neurological applications.
See also [GSK3 in Parkinson's Disease](/mechanisms/gsk3-parkinsons), [GSK3 in Parkinson's Disease - Disease Focus](/mechanisms/gsk3-parkinsons-disease), and [PD Kinase Inhibitor Companies](/companies/pd-lrrk2-kinase-inhibitor-companies).
References
[Golpich M, et al. Glycogen synthase kinase 3 beta (GSK-3β) signaling in Parkinson's disease. Cell Mol Neurobiol. 2017.](https://pubmed.ncbi.nlm.nih.gov/28467065/)
[Yuan YH, et al. GSK-3β and α-synuclein in Parkinson's disease. Behav Brain Res. 2020.](https://pubmed.ncbi.nlm.nih.gov/32004565/)
[Chiu CC, et al. Lithium therapy for Parkinson's disease. Transl Neurodegener. 2013.](https://pubmed.ncbi.nlm.nih.gov/24244175/)
[Lovestone S, et al. A phase II trial of tideglusib in Alzheimer's disease. J Alzheimers Dis. 2015.](https://pubmed.ncbi.nlm.nih.gov/25824332/)Pathway Diagram
The following diagram shows the key molecular relationships involving PD GSK3 Inhibitor Companies discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)